Select Sidearea

Populate the sidearea with useful widgets. It’s simple to add images, categories, latest post, social media icon links, tag clouds, and more.
[email protected]

About Us

About Neoolife, Inc.

Neoolife, Inc. is a pre-clinical stage Bio-MedTech start-up based in the United States and with a presence in Europe.


Neoolife includes an international, multidisciplinary team with more than 130 years of cumulative experience in biomedical technology and device therapy. Our business team has a recognized track of leadership in both large corporations and start-ups.


Our worldwide recognized bio/chemical/mechanical engineers and cardiovascular physicians have a long-lasting involvement in the research & development, clinical, and academic fields of cardiovascular disease.


We focus on tissue-engineered Biomimetic Heart Valves (BMHV) and tissue-engineered Biomimetic Cardiovascular Patches (BMCP) that enable endogenous in situ tissue regeneration. Our technology is used for percutaneous and surgical applications.


Neoolife is also developing unique solutions for the percutaneous treatment of heart valve disease, i.e., tricuspid valve regurgitation.


Neoolife polymeric tissue-engineered biomimetic products are durable, non-thrombogenic, and resistant to calcification.

Our Leadership Team

David Kokot HS

David Kokot

President and CEO

David Kokot is a medical device professional in the endovascular and structural heart business with more than 16 years of experience in different leadership roles in  Medtech Corporates (Medtronic Inc, Boston Scientific Inc.), and startup companies. His expertise in business development, sales, clinical, and marketing is supporting the development of Neoolife.

Antonio D’Amore, PhD

Chief Technology Officer

Dr. Antonio D’Amore holds a Ph.D. in Biomechanics and Tissue Engineering, and he has spent the last 15 years developing the polymeric technology of Neoolife. He is the head of cardiac tissue engineering with RiMED, and he has more than 15 inventions in the cardiovascular tissue engineering field. Dr. D’Amore has been a bioengineering industry consultant in both the U.S. and Europe.
Giuseppe D'Ancona HS

Giuseppe D’Ancona, MD, PhD

Chief Medical Officer

Dr. Giuseppe D’Ancona is a specialist in cardiac surgery and cardiology with an extensive 25 years of clinical and academic experience. He holds a Ph.D. in cardiovascular sciences, and he is focusing on innovations in cardiovascular medicine and percutaneous treatment of cardiovascular disease. Dr. D’Ancona’s clinical and scientific experience has supported developing, testing, and improving technologies in collaboration with large corporates and startup companies.
Garrett Coyan HS

Garrett Coyan, MD, MS

Vice President of Innovations & Strategy

Dr. Garrett Coyan is a Cardiothoracic Surgeon with a focus on cardiovascular engineering. He holds a BS in Biochemistry focusing on tissue engineering and regenerative technologies and an MS in Clinical and Translational Research. He has formal training in medical product development and regulatory strategy, with demonstrated expertise in pre-clinical and clinical study design.
William Wagner HS

William R. Wagner, PhD

Chair Scientific Advisory Board

Dr. William R. Wagner is a distinguished Professor of Surgery, Bioengineering, and Chemical Engineering. He holds a Ph.D. in Chemical Engineering and is the director of the prestigious McGowan Institute for regenerative medicine. In his over 25-year professional experience, Dr. Wagner has become a worldwide recognized authority in the field of bioengineering and particularly in cardiovascular engineering. His research has generated numerous patents and patent filings that have resulted in licensing activity, the formation of a company that has reached clinical trials, and many Innovator Awards.

Vinay Badhwar, MD

Senior Medial Advisor

Dr. Vinay Badhwar is Professor and Chairman of the department of cardiovascular and thoracic surgery. He has more than 25 years of clinical and research experience in the cardiovascular field. He is an internationally recognized key opinion leader in cardiac surgery and specifically in the field of treatment of heart valve disease.  Dr. Badhwar has been supporting important innovations introducing revolutionary treatment modalities, including key-hole and robotic heart-valve surgery.